BSc, MSc, PhD
Dr Lizeth Orozco is part of the Sarcoma Translational Research team and is currently working on improving responses to immunotherapy by targeting novel targets in combination with standard care of immunotherapy.
Lizeth graduated from ITESM campus Guadalajara, in Mexico, in 2013 with a Bachelor of Science majoring in Biotechnology Engineering. She then completed a Master of Science in Stem Cell Technology in 2016 at the University of Nottingham in UK.
In 2018, Lizeth started her PhD at the National Centre for Asbestos Related Diseases in Perth, Western Australia, focusing on mesothelioma and identification of novel therapy targets.
Early in 2023, she completed her PhD in Biomedical Sciences. In 2022, while completing her PhD, she was hired as a Research Officer in the Sarcoma Translational Research team where she also works as Biological Lead in Setonix Pharmaceuticals, in the project ‘Enhancing immuno-oncology with small molecules drugs’, with the main goal of targeting specific molecules to improve immunotherapy outcomes for cancer patients.